ISCO — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• The following table summarizes our results of operations for the three months ended June 30, 2026 and 2025 (in thousands, except percentages):

• Product sales for the three months ended June 30, 2026 were $2,675 thousand compared to $2,447 thousand for the three months ended June 30, 2025. This increase was driven by an increase in product sales from our biomedical market segment, including an increase of $410 thousand from our media product…

• Cost of sales for the three months ended June 30, 2026 were $1,217 thousand, compared to $927 thousand for the three months ended June 30, 2025. The increase of $290 thousand, or 31%, was primarily attributable to an increase of approximately $258 thousand in cost of sales from our biomedical market…

• Profit margins as a percentage of revenue have decreased approximately 7% for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025. The net decrease in gross margins was a result of the normalization in profit margins related to our skin care market segment as co…

• Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products, as well as related direct materials, general laboratory supplies and the allocation of overhead.

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• Comparison of the Three Months Ended March 31, 2026 and 2025

• The following table summarizes our results of operations for the three months ended March 31, 2026 and 2025 (in thousands, except percentages):

• Product sales for the three months ended March 31, 2026 were $2,315 thousand compared to $2,129 thousand for the three months ended March 31, 2025. The increase of $186 thousand, or 9%, was as a result of an increase in product sales from our biomedical market segment, including an increase of $140 …

• Cost of sales for the three months ended March 31, 2026 were $954 thousand, compared to $992 thousand for the three months ended March 31, 2025. The decrease of $38 thousand, or 4%, was as a result of approximately $70 thousand decrease in net cost of goods from our skin care product line as a resul…

• Profit margins as a percentage of revenue was 59% versus 53% for the three months ended March 31, 2026 and 2025, respectively. The increase in margins was as a result of approximately 2% increase from our biomedical market segment driven by a slight change in the sales mix generating higher margins.…

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and…

• designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate, to allow timely …

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and…

Text added vs the prior filing · source: 10-Q · 2026-08-13

• The Transaction may not be completed on the anticipated timeline or at all.

• The completion of the sale of 100% of the membership interests in LCT to ATCC pursuant to the MIPA is subject to numerous closing conditions, many of which are beyond the Company’s control. These conditions include, among others, the accuracy of each party’s representations and warranties, the perfo…

• The MIPA provides that either party may terminate the agreement if the closing has not occurred within 60 days of execution (subject to automatic extension in the event of SEC review delays). While stockholder approval has been obtained via written consent of the requisite holders, the Information S…

• The MIPA may be terminated under certain circumstances, and the Company may be unable to complete the Transaction due to events beyond its control.

• The MIPA contains a number of termination provisions that could prevent the Transaction from being completed. The MIPA may be terminated by: (a) mutual written consent of the parties; (b) either party if the closing has not occurred within 60 days (with automatic extension for SEC review delays), pr…